Detection and quantification of CSF malignant cells by the CellSearch ® technology in patients with melanoma leptomeningeal metastasis

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Le Rhun, Emilie ^a,b   Tu, Qian ^c,d   De Carvalho Bittencourt, Marcelo ^c,d   Farre, Isabelle ^a   Mortier, Laurent ^b,e   Cai, Huili ^c,d   Kohler, Chantal ^c,d   Faure, Gilbert C ^c,d  

^a CENTRE OSCAR LAMBRET   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

^e UNIV LILLE   (France)

Author keywords

CellSearch technology; CSF cytology; Immunomagnetic enrichment; Leptomeningeal metastasis; Melanoma; Neoplastic meningitis

Indexed keywords

B RAF KINASE; CYTARABINE; EPITHELIAL CELL ADHESION MOLECULE; GADOLINIUM; TEMOZOLOMIDE; VEMURAFENIB; TUMOR MARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CASE REPORT; CELL STRUCTURE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CYTOLOGY; DIAGNOSTIC KIT; FOLLOW UP; HUMAN; LEPTOMENINGEAL METASTASIS; MALE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; CELL COUNT; MENINGIOMA; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TUMOR EMBOLISM;

CELL COUNT; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MENINGEAL NEOPLASMS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; TUMOR MARKERS, BIOLOGICAL;

EID: 84874937955     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0538-3     Document Type: Article

References (20)

1. Moseley RP, Davies AG, Bourne SP, Popham C, Carrel S, Monro P, et al. Neoplastic meningitis in malignant melanoma: diagnosis with monoclonal antibodies. J Neurol Neurosurg Psychiatry. 1989;52:881-6.
2. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42:660-8.
3. Pape E, Desmedt E, Zairi F, Baranzelli MC, Dziwniel V, Dubois F, Bonneterre J, Mortier L, Le Rhun E. Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients. In Vivo. 2012;26(6):1079-86.
4. Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol. 2008;10:1010-8.
5. Carlino MS, Fogarty GB, Long GV. Treatment of melanoma brain metastases: a new paradigm. Cancer J. 2012;18(2):208-12.
6. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman RB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicenter, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087-95.
7. Chamberlain MC. Leptomeningeal metastasis. Curr Opin Neurol. 2009;22:665-74.
8. Koyanagi K, O'Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, et al. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 2010;16(8):2402-8.
9. Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest. 2009;119(10):3172-81.
10. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235-9.
11. Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang HJ, et al. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg. 2012;255(2):357-62.
12. Rao C, Bui T, Connelly M, Doyle G, Karydis I, Middleton MR, et al. Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol. 2011;38(3):755-60.
13. Clawson GA, Kimchi E, Patrick SD, Xin P, Harouaka R, Zheng S, et al. Circulating tumor cells in melanoma patients. PLoS ONE. 2012;7(7):e41052.
14. Weston CL, Glantz MJ, Connor JR. Detection of cancer cells in the cerebrospinal fluid: current methods and future directions. Fluids Barriers CNS. 2011;8(1):14.
15. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421.
16. Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2011;2(10):752-60.
17. Le Rhun E, Massin F, Tu Q, Bonneterre J, Bittencourt MD, Faure GC. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012;12(1):21.
18. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl J Med. 2004;351(8):781-91.
19. De Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;15(19):6302-9.
20. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbah KD, Gabrai NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213-21.